WASHINGTON (dpa-AFX) - AbbVie (ABBV) on Thursday said that Canada's Drug Agency (CDA-AMC) has recommended ELAHERE for reimbursement with conditions for the treatment of patients with certain types of platinum-resistant ovarian cancer.
The company noted that ELAHERE was submitted for reimbursement review 180 days before Health Canada's approval, in alignment with CDA-AMC's Target Zero initiative, which aims to accelerate patient access to new therapies.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
